Filing Details
- Accession Number:
- 0001012975-15-000017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-12 09:44:15
- Reporting Period:
- 2015-01-08
- Filing Date:
- 2015-01-12
- Accepted Time:
- 2015-01-12 09:44:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1337553 | Aerie Pharmaceuticals Inc | AERI | Biological Products, (No Disgnostic Substances) (2836) | 203109565 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1166285 | Michael Steinmetz | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1249153 | Dennis Henner | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | Yes | No | Yes | No | |
1252522 | Nicholas Galakatos | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1252523 | Robert Liptak | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1252525 | Kurt Wheeler | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431403 | Nicholas Simon | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431437 | Clarus Ventures Ii, Llc | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431439 | Clarus Ventures Ii Gp, L.p. | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431443 | Clarus Lifesciences Ii, L.p. | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-01-08 | 175,000 | $31.11 | 3,324,259 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $31.00 to $31.25 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.